Skip to main content

Advertisement

Table 4 Risk factors analyzed by univariate and multivariate (Cox regression models) for disease-free survival (DFS) and overall survival (OS)

From: Surveillance for early stages of colon cancer: potentials for optimizing follow-up protocols

  Univariate analysis Multivariate analysis
  DFS HR (95 % CI) OS HR (95 % CI) DFS HR (95 % CI) OS HR (95 % CI)
Gender
Female 1 1 1 1
Male 0.59 (0.25–1.40) 0.57 (0.21–1.57) 0.41 (0.16–1.05) 0.41 (0.14–1.25)
Age, years 1.06 (1.01–1.12) 1.09 (1.02–1.16) 1.07 (1.01–1.12) 1.09 (1.02–1.16)
Budding
 No 1 1 1 1
 Yes 1.72 (0.67–4.44) 1.09 (0.31–3.85) 1.22 (0.35–4.16) 1.06 (0.23–4.87)
Fibrosis
 <50 % 1 1 1 1
 > = 50 % 1.98 (0.77–5.10) 1.23 (0.35–4.35) 1.21 (0.37–3.94) 1.01 (0.22–4.61)
Stage
 1 1 1 1 1
 2A 1.11 (0.42–2.93) 0.80 (0.26–2.46) 1.08 (0.35–3.30) 1.13 (0.31–4.13)
 2B 2.89 (0.58–14.35) 3.68 (0.71–19.00) 4.07 (0.63–26.08) 5.81 (0.77–43.92)
Lymph nodes retrieved
 > = 12 1 1 1 1
 <12 2.56 (1.09–6.25) 2.70 (1.03–7.69) 2.13 (0.76–5.88) 2.38 (0.71–8.33)
Vascular invasion
 No 1 1 1 1
 Yes 3.78 (1.12–12.91) 3.19 (0.72–14.15) 3.43 (0.87–13.58) 2.91 (0.59–14.31)
Lymphatic invasion
 No 1 1 1 1
 Yes 1.71 (0.63–4.67) 0.83 (0.19–3.69) 0.88 (0.26–2.94) 0.85 (0.09–2.89)
Site
 Right or trasversum 1 1 1 1
 Left or double 2.69 (1.04–6.93) 2.06 (0.70–6.04) 3.56 (1.24–10.21) 3.34 (0.98–11.84)
Chemotherapy
 No 1 1 1 1
 Yes 1.12 (0.38–3.34) 0.76 (0.17–3.37) 1.52 (0.39–5.97) 1.37 0.24–7.99)
  1. HR hazard ratio
  2. CI confidential interval